About LunaDNA
LunaDNA operates a community-owned health and DNA data platform that empowers individuals to contribute their health and genetic information to medical research while retaining ownership of their data. The company's platform enables members to share their health data, DNA information, and other medical records with researchers and pharmaceutical companies in a secure, consent-based environment. LunaDNA's unique model allows participants to become shareholders in the platform, creating a community where members benefit directly from the value their data generates. The platform facilitates precision medicine research by aggregating diverse health datasets that researchers can access with explicit participant consent. By combining genomic data with longitudinal health information, LunaDNA supports studies aimed at understanding disease mechanisms, developing targeted therapies, and advancing personalized medicine. The company serves researchers, pharmaceutical companies, and biotechnology firms seeking access to consented, high-quality health data while prioritizing participant privacy, data security, and equitable benefit-sharing.
Who It Serves
Social & Media
Follow on
Company Details
Work here?
Claim this listing to update company information and connect with our audience.
Claim This ListingOfficial Sources
Similar Companies in this Market
View all 60 →23andMe
23andMe uses AI to analyze genetic data and provide personalized health summaries, risk assessments, and wellness recommendations based on genomic insights.
2bPrecise
AI-powered precision medicine platform for personalized treatment recommendations and genomic analysis.
ACT Genomics
AI-powered genomic analysis platform for precision medicine and personalized treatment recommendations.
Adaptive Biotechnologies
Adaptive Biotechnologies uses AI and machine learning to decode the immune system and identify disease-specific immune signatures for diagnosis and personalized treatment.
Ambry Genetics
Ambry Genetics is a leading clinical genetic testing laboratory specializing in hereditary cancer, rare disease, cardiology, and neurology testing. The company provides advanced genetic testing solutions with paired DNA/RNA analysis and comprehensive patient support programs.
Ataraxis
Ataraxis develops AI-native precision medicine tools that predict patient outcomes and treatment response in oncology. Their flagship product, Ataraxis Breast, provides clinically validated prognostic and predictive tests for breast cancer using multi-modal AI analysis of pathology images and clinical data.
Avenda Health
Avenda Health develops Unfold AI, an FDA-cleared artificial intelligence platform that creates 3D cancer estimation maps for prostate cancer. The technology analyzes standard-of-care data (MRI, biopsy, pathology, PSA) to visualize cancer location and extent, helping physicians make more informed treatment decisions and improve patient outcomes.
Base Genomics
Base Genomics appears to be a company in the Precision Medicine & Genomics space, but the scraped website content is empty or inaccessible, preventing detailed analysis of their offerings and target market.
Data Accuracy Notice: Company information on HealthAI Central is compiled from public sources and updated regularly. While we strive for accuracy, details such as funding figures, employee counts, and product offerings may change. We recommend verifying critical information directly with the company before making business decisions.